# Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy

> **NCT00084487** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer
- Limited Stage Small Cell Lung Cancer
- Recurrent Small Cell Lung Cancer

## Interventions

- **DRUG:** becatecarin

## Key facts

- **NCT ID:** NCT00084487
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-04
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00084487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00084487, "Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00084487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*